Vaccine composition

Details Vaccine composition Vaccine composition

2007-05-22

2007-05-22

Campell, Bruce R. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S197110, C424S237100, C424S244100, C435S023000, C530S350000, C536S023700

Reexamination Certificate

active

09959594

ABSTRACT:
A polypeptide is described herein which comprises (a) the sequence of SEQ ID No. 2, (b) a variant of (a) which is capable of generating a protective immune response toS. pyogenes, or (c) a fragment of (a) or (b) of at least 6 amino acids in length which is capable of generating a protective immune response toS. pyogenes, in the manufacture of medicament for use as a vaccine againstS. pyogenes. A pharmaceutical composition for use in vaccinating againstS. pyogenesor Group Bstreptococcuscomprises a polypeptide which comprises: (A) the amino acid sequence of SEQ ID No. 2, (B) a variant of (A) which is capable of conferring protective immunity toS. pyogenesor Group Bstreptococcus, or (C) a fragment of (A) or (B) of at least 6 amino acids in length which is capable of conferring protective immunity toS. pyogenesor Group Bstreptococcus.

REFERENCES:
patent: 6015889 (2000-01-01), Lindahl et al.
patent: 6586580 (2003-07-01), Lindahl et al.
patent: 0 200 909 (1986-12-01), None
patent: 0 367 890 (1990-05-01), None
patent: WO 89/07649 (1989-08-01), None
patent: WO 94 10317 (1994-05-01), None
patent: WO 94/21685 (1994-09-01), None
patent: WO 98 06428 (1998-02-01), None
Fenderson et al ; J. Immunol., Apr. 1989; 142: 2475-2481.
Clinical Microbiological Reviews 2000, 13, 470-511.
Rudinger et al, in “Peptide Hormones”, edited by Parsons, J.A., University Park Press, Jun. 1976, p. 6.
Burgess et al., The Journal of Cell Biology, 111:2129-2138, 1990.
Lazar et al., Molecular and Cellular Biology, 8(3): 1247-1252, 1988.
Jobling et al. (Mol. Microbiol. 1991, 5(7): 1755-67.
1999, Mol.Microbio, 33(1) 208).
Johnson 1975 (Infect Immun. 1975 Oct; 12(4): 901-9).
Michel et al 1992, Database PIR—78, Acession No. 46405. Proc Natl Acad Sci U S A. Nov. 1, 1992;89(21): 10060-4.
Wastefelt et al 1996, Database GenEmbl, Acession No. SAU 58333 (for nucleic acid sequence), Database SPTREMBL, Accession No. Q9XDB6 (for amino acid sequence). J.B.C. 1996, 271(3), 18892-18897.
Clinical Microbiological Reviews 1998, 11; 497-513.
Chappell et al, “Demonstration of protection in mice from a lethal challenge of three M serotypes ofStreptococcus pyrogensusing an M-negative vaccine”, Vaccine, GB, Butterworth Scientific, Guildford, vol. 11, 1993, pp. 643-649.
Wäsfelt, “Identification of a family of streptococcal surface proteins with extremely repetitive structure”, Journal of Biological Chemistry, vol. 271, No. 31, 1996, pp. 18892-18897.
Stalhammar-Carlemalm et al, “The R28 protein ofStreptococcus pyrogensis related to several Group B streptococcal surface proteins, confers protective immunity and promotes binding to human epithelial cells” Molecular Microbiology, vol. 33, No. 1, Jul. 1999, pp. 208-219.
Stalhammar-Carlemalm et al, “Cross-protection between group A and group BStreptococcidue to cross-reacting surface proteins”, Journal of Infectious Diseases, vol. 182, No. 1, Jul. 2000, pp. 142-149.
Lachenauer et al, “Mosaicism in the alpha-like protein genes of group BStreptococci” Proceedings of the National Academy of Sciences of the United States, vol. 97, No. 17, Aug. 15, 2000, pp. 9630-9635.
Stanley et al, “molecular Subtyping of Prevalent M Serotypes ofStreptococcus pyrogenesCausing Invasive Disease”, Journal of Clinical Microbiology, Nov. 1995, pp. 2850-2855.
Larsson et al, “Experimental Vaccination against Group BStreptococcus, an Encapsulated Bacterium, with Highly Purified Preparations of Cell Surface Proteins Rib and α”, Infection and Immunity, Sep. 1996, pp. 3518-3523.
Lancefield et al. “Preparation and properties of a protein (R antigen) occurring inStreptococciof group A, type 28 and in certainStreptococciof other serological groups” J. Exp. Med. 96:83-97 (1952).
Michel et al. “Large, identical, tandem repeating units in the C protein alpha antigen gene,bca, of group BStreptococci” Proc. Natl. Acad. Sci. USA 89:10060-10064 (1992).

Affiliated with

Also associated with

Rating

Vaccine composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3805456